(Q37257896)

19 August 2017

1 reference

title

Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

1

G R Davies

1 reference

19 August 2017

E L Nuermberger

2

1 reference

19 August 2017

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

88 Suppl 1

1 reference

19 August 2017

S65-74

1 reference

Pharmacokinetic-pharmacodynamic modelling: history and perspectives

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetic/pharmacodynamic modeling in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

How modeling and simulation have enhanced decision making in new drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Reactivation of latent tuberculosis: variations on the Cornell murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The temporal expression profile of Mycobacterium tuberculosis infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Early bactericidal activity of antituberculosis agents

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetics of isoniazid metabolism in man

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Population screening for isoniazid acetylator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Biological Acetylation of Isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Isoniazid activity is terminated by bacterial persistence

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Bactericidal Activity of Streptomycin, Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Alone and In Combination Against Mycobacterium Tuberculosis1

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Laboratory aspects of intermittent drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Xanthine oxidase activity is influenced by environmental factors in Ethiopians

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Clinical Pharmacokinetics of Rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Regimens of less than six months for treating tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Rifapentine for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Fluoroquinolones and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Fluoroquinolones, tuberculosis, and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

The Rapid Development of Fluoroquinolone Resistance inM. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2808%2970037-4

7 January 2021

10.1016/S1472-9792(08)70037-4

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18762154